Ucler KİSA, Murat ALPUA

Is there any association between microalbuminuria and Parkinson’s disease?

Aim: To investigate microalbuminuria in patients with Parkinson’s disease (PD) and to determine its relationship with the stages of the disease. Parkinson’s disease (PD) is a chronic neurodegeneration of dopaminergic neurons in the substantia nigra. The reason for the death of these neurons is still unclear; however, studies have demonstrated the potential involvement of mitochondria, endoplasmic reticulum in contributing to cellular oxidative stress.Material and Methods: Thirty-two PD patients who admitted to Neurology Clinic of Kirikkale University’s Medical Faculty and 30 healthy volunteers whose age and sex-matched were included in the study. Urine creatinine and urine albumin levels were determined in patient and healthy groups. The disease duration and Hoehn and Yahr stages were recorded.Results: There was no statistically significant difference between urine creatinine, microalbumin, and urine creatinine/albumin ratios when PD patient results compared with the healthy volunteers’. There was no significant correlation among urine creatinine, microalbumin, and urine creatinine/albumin ratio between the disease duration and Hoehn and Yahr staging in patients with PD.Conclusion: Microalbuminuria is an indirect finding of oxidative stress in urine. In the current study, microalbuminuria was not detected in PD patients at various stages of the disease. It is an important finding that microalbuminuria, a marker of oxidative stress in the urine in PD, a disease in which oxidative stress plays a significant role in etiopathogenesis, is not found.

PDF

___

1. Fahn S, Przedborski S. Parkinsonizm. In: Rowland LP, ed. Merritt’s Textbook of neurology. 10 th ed. Philadelphia, Md: Lippincott Williams & Wilkins; 2000:679-93.
2. Hwang O. Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 2013;22:11-7.
3. Vinish M, Anand A, Prabhakar S. Altered oxidative stress levels in Indian Parkinson’s disease patients with PARK2 mutations. Acta biochim Pol 2011;58:165-9.
4. Medeiros MS, Schumacher-Schuh A, Cardoso AM, et al. Iron and oxidative stress in Parkinson’s disease: an observational study of injury biomarkers. PLoS One 2016;11:e0146129.
5. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43.
6. Vicentini J, Valentini J, Grotto D, et al. Association among microalbuminuria and oxidative stress biomarkers in patients with type 2 diabetes. J Investig Med 2011;59:649-54.
7. Jacobs DR, Murtaugh MA, Steffes M, et al. Gender and race specific determination of albumin excretion rate using albumin-tocreatinine ratio in single, untimed urine specimens. The study of coronary artery risk development in young adults. Am J Epidemiol 2002;155:1114-9.
8. Casanova C, de Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:1004-10.
9. Farias LB, Lavinsky D, Benfica CZ, et al. Microalbuminuria ıs associated with early retinal neurodegeneration in patients with type 2 diabetes. Ophthalmic Surg Lasers Imaging Retina 2018;49:e36-e43.
10. Alpua M, Turkel Y, Dag E, Kisa U.Is there any association between microalbuminuria and multiple sclerosis?. Neurology Asia 2016;21:295-7.
11. do Carmo FS, Pires SL, Gorzoni ML, et al. Cognitive and renal dysfunction in the elderly. Dement Neuropsychol 2013;7:397-402.
12. Ochodnicky P,Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006;47:151-62.
13. Muller T, Werne B, Fowler B, et al. Nigral endothelial dysfunction, homocysteine, and Parkinson’s disease. Lancet 1999;354:126-27.